Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma

BACKGROUND: Malignant pleural mesothelioma (MPM) is a very rare and highly aggressive cancer of the pleura associated in most cases with asbestos exposure. To date, no really efficient treatments are available for this pathology. Recently, it has been shown that epigenetic drugs, particularly DNA me...

Descripción completa

Detalles Bibliográficos
Autores principales: Bensaid, Douae, Blondy, Thibaut, Deshayes, Sophie, Dehame, Virginie, Bertrand, Philippe, Grégoire, Marc, Errami, Mohammed, Blanquart, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006850/
https://www.ncbi.nlm.nih.gov/pubmed/29946373
http://dx.doi.org/10.1186/s13148-018-0517-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006850/
https://www.ncbi.nlm.nih.gov/pubmed/29946373
http://dx.doi.org/10.1186/s13148-018-0517-9

Ejemplares similares